GLOBAL INDUSTRY INSIGHT:
Estrogen Receptor-Positive (ER+) Breast Cancer Pipeline Analysis, 2017
Estrogen
Receptor-Positive
(ER+)
Breast
Cancer
Pipeline
Analysis, 2017
According to a new research report “Estrogen Receptor-Positive (ER+) Breast Cancer
Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and
Other Developments” published by P&S Market Research, Estrogen Receptor-Positive (ER+)
breast cancer currently exhibits a pipeline with 46 active drug candidates.
Access
Report
Overview:
https://www.psmarketresearch.com/market-analysis/estrogen-
receptor-positive-breast-cancer-pipeline-analysis
The study analyzed that the estrogen receptor positive breast cancer pipeline comprises
approximately 74 drug candidates, of which nine products are in Phase III, 16 products in Phase II,
18 products in Phase I, and three products are in Pre-Clinical stage. The development of 14 ER+
breast cancer drug candidates was found to be inactive, and 14 products were discontinued. ER+
breast cancer is the most common type of breast cancer diagnosed and refers to the cancer cells
that have receptors on their surface to bind with estrogen. Breast cancer is a syndrome that affects
the breast tissues. In breast cancer, cells in the breast grow in an uncontrollable manner and form
tumor, which can be felt as a lump or can be viewed under x-ray. Invasion of new therapeutic
agents, such as gene therapy, cell therapy and monoclonal antibodies are expected to provide an
effective and concrete treatment for the disease, more in the light of the new technologies
available.
As per the findings of the research, a major share of ER+ breast cancer pipeline drug candidates
are being developed to be administered by oral route and rest by intravenous route and
subcutaneous route. Most of the therapeutic candidates are being developed to be administered by
oral route due to high patient compliance.
Several companies are developing ER+ breast cancer drug candidates in different phases. Novartis
AG, Syndax Pharmaceuticals, Tesaro, Inc. and others have their ER+ breast cancer drug candidates
in Phase III stage of development. Novartis AG has three drug candidates in Phase III stage and
two drug candidates in Phase I clinical stage.
Explore
Report
Sample
at:
https://www.psmarketresearch.com/market-analysis/estrogen-
receptor-positive-breast-cancer-pipeline-analysis/report-sample
Chipscreen Biosciences, Ltd. is using chemo genomics approach for the development of Chidamide
for ER+ breast cancer. The approach connects small molecule structures to disease targets and
therapeutic functions to accelerate the discovery process by effectively comparing the molecular
© P&S Market Research. All rights reserved
2
Estrogen
Receptor-Positive
(ER+)
Breast
Cancer
Pipeline
Analysis, 2017
profiles of successful drugs, failed drugs, and classical toxins. For the discovery of small molecules,
the company is following a comprehensive systemic approach, integrated with in silico design,
chemistries, high content screening, global gene expression profiling, and informatics in the early
stage of discovery.
There are nine ER+ breast cancer drug candidates in the Phase III stage of development.
Buparlisib is a Phase III stage drug candidate introduced by Novartis Pharmaceuticals for the
treatment of hormone receptor-positive (HR+) breast cancer. It is a small molecule that inhibits
PI3K and is administered by oral route. The product is also in Phase II stage of development for the
treatment of ER+ breast cancer.
Browse
Other
Related
Report
at:
https://www.psmarketresearch.com/industry-
report/pharmaceuticals
The research finds that different companies have collaborated for the development of ER+ breast
cancer. In May 2015, Tesaro, Inc entered in a collaboration with Merck & Co. to evaluate the
combination of Tesaro’s Niraparib plus Merck’s anti-PD1 therapy, Keytruda (pembrolizumab), in a
Phase 1/2 clinical trial. Also, in January 2016, Radius Health, Inc. entered in a worldwide clinical
collaboration with Novartis Pharmaceuticals to evaluate the safety and efficacy of combining
investigational agent RAD1901 with LEE011 for advanced breast cancer.
Some of the key players developing drugs for Estrogen Receptor-Positive (ER+) breast cancer are
Chipscreen Biosciences, Ltd., Eli Lilly & Company, Genentech, Inc., Novartis AG, Ipsen, Syndax
Pharmaceuticals, Inc., Tesaro, Inc Astellas Pharma Inc., AstraZeneca plc, and Bayer AG.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for
various geographies around the globe. We provide market research reports, industry forecasting reports,
business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate
forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through
their interaction with leading companies of the concerned domain. We help our clients with B2B market research
and assist them in identifying various windows of opportunity, and framing informed and customized business
expansion strategies in different regions.
© P&S Market Research. All rights reserved
3
Estrogen
Receptor-Positive
(ER+)
Breast
Cancer
Pipeline
Analysis, 2017
Contact:
Kundan
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-Free: +1-888-778-7886 (USA/Canada)
Email: [email protected]
Web: https://www.psmarketresearch.com
© P&S Market Research. All rights reserved
4